На главную
Видео добавленное пользователем “Targeted Oncology”
Dr. Tefferi on the Outlook for JAK Inhibitors in Myelofibrosis
 
02:43
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 3230 Targeted Oncology
Dr. Louis M. Weiner Explains Cell Autophagy
 
02:20
Louis M. Weiner, MD, Director, Lombardi Comprehensive Cancer Center, Associate Vice President, Georgetown University Medical Center, explains cell autophagy.
Просмотров: 5358 Targeted Oncology
Dr. Jeffrey Weitzel on Synthetic Lethality in BRCA-Associated Cancer
 
03:24
Jeffrey N. Weitzel, MD, Chief of the Division of Clinical Cancer Genetics at City of Hope, discusses the concept of synthetic lethality in BRCA-associated cancers. The concept of synthetic lethality suggests that when only one mutation or weakness is present the cancer cells will survive. However, when several are blocked or damaged the cancer cells die. This concept is being tested using the PARP inhibitor ABT-888 in BRCA-associated cancers. Weitzel explains that preliminary results looking at ABT-888 in BRCA-associated cancer is promising.
Просмотров: 1653 Targeted Oncology
Understanding the Prognosis of Metastatic Melanoma
 
04:32
Michael A. Davies, MD, PhD, reviews the case of a 52-year-old female patient who presents with newly diagnosed metastatic melanoma and describes the prognosis for this patient, highlighting the importance of excision margin guidelines and lymph node dissection. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1364 Targeted Oncology
Pembrolizumab Therapy for Microsatellite Instability-High Colorectal Cancer
 
02:03
Luis A. Diaz Jr., MD, head, Division of Solid Tumor Oncology, discusses pembrolizumab (Keytruda) therapy for microsatellite instability-high colorectal cancer and other tumor types.
Просмотров: 630 Targeted Oncology
Polycythemia Vera Disease Burden
 
04:41
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1407 Targeted Oncology
Dr. Jae Park Comments on the Treatment of Hairy Cell Leukemia
 
01:33
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1243 Targeted Oncology
Overall Survival Results for Encorafenib Plus Binimetinib in BRAF-Mutant Melanoma
 
02:47
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival (OS) results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in BRAF-mutant melanoma during the 2018 ASCO Annual Meeting. Earlier results showed the median progression-free survival rate for the combination of encorafenib and binimetinib was just under 15 months, which is a few months longer than what has been achieved with any other melanoma therapy that has recently emerged. Strikingly, the median OS was just over 33 months, which is also markedly longer than what has previously been seen. These results represent quite a striking milestone in this disease, Flaherty says. Patients typically stay on this therapy for a long time, so safety and tolerability are critically important, he notes. The tolerability of this regimen is also best-in-class. It shares some of the same toxicities as other BRAF/MEK combinations, but it lacks some of the major toxicities that are associated with these regimens, which is a significant benefit of this combination. For more coverage of the 2018 ASCO Annual Meeting: http://www.targetedonc.com/conference/asco-2018
Просмотров: 475 Targeted Oncology
Treating Brain Metastases in Patients With Lung Cancer
 
01:39
Manmeet Ahluwalia, MD, Cleveland Clinic, discusses treatments that are showing promise for patients with lung cancer who develop brain metastases.
Просмотров: 556 Targeted Oncology
Dr. Röllig on FLT3 ITD/NPM1 Mutation Status for Patients With AML
 
02:09
Christoph Röllig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with acute myeloid leukemia (AML) who are in first remission. Röllig says that it is important to balance relapse risk, as well as risks associated with different consolidation treatments. There are two main options: chemo-consolidation with high dose cytarabine and alogeneic stem cell transplantation. He adds that alogeneic stem cell transplantation is associated with a higher treatment-related mortality and lower relapse rate. With chemo-consolidation, tolerability is better but the relapse rate is higher. Röllig believes that we are learning more about minimal residual disease (MRD), which will enable physicians to taylor treatment to the level of response in MRD. He concludes that targeted therapies for patients with this mutation status will become available, such as tyrosine-kinase inhibitors (TKIs).
Просмотров: 703 Targeted Oncology
Dr. Elizabeth Mittendorf on the E75 Vaccine for Breast Cancer
 
02:17
Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Просмотров: 1479 Targeted Oncology
The Prognosis of Myelofibrosis
 
05:06
Srdan Verstovsek, MD, discusses the case of a 59-year-old male patient who presents with myelofibrosis and the prognostic factors to consider for such a patient. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 954 Targeted Oncology
Dr. Motzer on Sunitinib Versus Pazopanib in Renal Cell Carcinoma
 
02:32
Robert J. Motzer, MD, attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, discusses the use of pazopanib compared with sunitinib as first-line therapy for patients with renal cell carcinoma. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Просмотров: 957 Targeted Oncology
Diagnosis and Prognosis of Stage 4 Lung Adenocarcinoma
 
03:54
Mark A. Socinski, MD, gives his initial impression of the diagnosis and prognosis of a 64-year-old man with stage 4 lung adenocarcinoma. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1348 Targeted Oncology
Dr. Al-Batran on FLOT Benefit in Gastric Cancer
 
01:56
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 482 Targeted Oncology
Determining Prognosis of Follicular Lymphoma
 
03:08
Ajay Gopal, MD, reviews the case of a 66-year-old male patient who presents with inguinal and axillary lymphadenopathy, as well as the patient’s prognosis at diagnosis. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 650 Targeted Oncology
Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer
 
03:01
H. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient. Currently, physicians have a great problem, according to West, with a number of positive trials with these agents, including monotherapies, chemotherapies, chemotherapy regimens, and immunotherapies. Of this data, a lot has been found with pembrolizumab and West is expecting to see a broader indication approved for this agent. In squamous NSCLC, the KEYNOTE-407 trial demonstrated positive results in progression-free survival (PFS) and overall survival (OS) with pembrolizumab combined with carboplatin and nab-paclitaxel. PFS benefit was also found in the Impower131 trial investigating carboplatin with nab-paclitaxel plus atezolizumab. However, West says he does not believe the atezolizumab combination will be as favored because there is not an OS improvement. West says the data points to pembrolizumab as the better option, with the only question being whether to give it alone or in combination with chemotherapy. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/resource-center/lung
Просмотров: 459 Targeted Oncology
Dr. David B. Solit on Inhibiting KRAS, HRAS, NRAS, and BRAF Genes
 
01:40
David B. Solit, MD, Associate Professor of Medicine, clincal oncologist, Memorial Sloan-Kettering Cancer Center, explains the goal and role of his laboratory. Solit explains that KRAS, HRAS, NRAS, and BRAF genes make cancer cells grow and progress, and are therefore good targets.
Просмотров: 1127 Targeted Oncology
Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors
 
01:41
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors. Strosberg says this targeted therapy is especially useful due to neuroendocrine tumors generally having high-expressing somatostatin expressers. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1099 Targeted Oncology
Diagnosis of Stage 3 Prostate Cancer
 
04:31
Daniel J. George, MD, describes the management of a patient with stage 3 prostate cancer and the subsequent development of progressive disease. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 374 Targeted Oncology
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
 
01:18
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Просмотров: 327 Targeted Oncology
Long-Term Results of Post-Prostatectomy Radiotherapy
 
01:25
Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Просмотров: 641 Targeted Oncology
Therapy for Relapsed Follicular Lymphoma
 
06:15
Loretta J. Nastoupil, MD, provides insight on the options for therapy in patients who develop relapsed follicular lymphoma and the concern for transformation to large-cell lymphoma. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 397 Targeted Oncology
Initial Treatment for Polycythemia Vera
 
06:15
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 410 Targeted Oncology
Dr. Churpek Discusses the ATM, CHEK2, and PTEN Genes in Breast Cancer
 
01:27
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Просмотров: 1055 Targeted Oncology
Nivolumab With Ipilimumab for Small Cell Lung Cancer
 
03:17
Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study, which explored nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
Просмотров: 602 Targeted Oncology
Dr. Aleksander Sekulic Explains the Hedgehog Pathway
 
02:20
Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, explains the hedgehog pathway, why it is crucial to cell development and growth and what role it plays in cancer. For more resources visit: http://targetedhc.com
Просмотров: 551 Targeted Oncology
The Role of Abiraterone in Prostate Cancer
 
02:06
Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate (Zytiga) in the treatment of patients with prostate cancer, and the questions that remain about its use.
Просмотров: 684 Targeted Oncology
Dr. Fuchs on Aspirin and Targeting COX-2 in Colorectal Cancer
 
03:51
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, on the use of aspirin and targeting COX-2 in colorectal cancer For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 950 Targeted Oncology
Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma
 
01:03
Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.
Просмотров: 368 Targeted Oncology
Dr. Georgina Long on the Treatment of Melanoma  With Emerging Targeted Therapies
 
02:35
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses the treatment of melanoma with emerging targeted therapies. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1073 Targeted Oncology
Dr. Yuri Nikiforov on the Genetic Evolution of Thyroid Cancer
 
02:47
Yuri E. Nikiforov, MD, PhD, Director of the Division of Molecular Anatomic Pathology, Department of Pathology, University of Pittsburgh, discusses a study that examined pathological and molecular trends in thyroid cancer since 1973. For more information on biomarkers, visit http://www.targetedhc.com/targeted/biological-markers
Просмотров: 864 Targeted Oncology
High-Grade Undifferentiated Pleomorphic Sarcoma
 
02:22
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 858 Targeted Oncology
Diagnosis of Stage III Colon Cancer
 
05:00
Tanios Bekaii-Saab, MD, FACP, discusses the management of a 51-year-old male patient diagnosed with stage T3N0M0 adenocarcinoma of the colon as a result of a routine screening colonoscopy, and highlights the screening guidelines. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1165 Targeted Oncology
David Berz, MD, PhD, and Philip Bonomi, MD Discuss Molecular Diagnostics in NSCLC
 
02:44
David Berz, MD, PhD, clinical oncologist, Beverly Hills Cancer Center, and Philip Bonomi, MD, professor, Rush Univeristy Medical Center, discuss the treatment options available to patients like Naoko T., a 74-year-old retired high school teacher originally from Nagoya, Japan, who was diagnosed with NSCLC after presenting to her PCP with dyspnea and intermittent back and chest pain. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 400 Targeted Oncology
Dr. Neal Young on the Evolving Treatment for Patients Diagnosed With Aplastic Anemia
 
01:30
Neal Young, MD, chief, Intramural Research Hematology Branch, National Heart, Lung, and Blood Institute, discusses the advancement of treatment for aplastic anemia. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 436 Targeted Oncology
Dr. Ma on the Utility of the CA 19-9 Test in Patients With Pancreatic Cancer
 
01:28
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 6522 Targeted Oncology
Treatment for Metastatic Pancreatic Cancer
 
03:42
George Kim, MD, discusses the patient’s prognosis of pancreatic cancer and the goals of his therapy, as well as the options for chemotherapy and patients’ concerns about the effect on quality of life. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 496 Targeted Oncology
The Future of Treatment of Mantle Cell Lymphoma
 
04:34
Michael L. Wang, MD, discusses up-and-coming treatment options for patients with mantle cell lymphoma and expresses hope to one day find a cure. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 752 Targeted Oncology
Single-Cell RNA Sequencing in Merkel Cell Carcinoma
 
01:51
Kelly Paulson, MD, PhD, a fellow at Seattle Cancer Care Alliance, discusses single-cell RNA sequencing in merkel cell carcinoma during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Просмотров: 215 Targeted Oncology
Dr. Woyach on BTK Inhibition and the Mechanism of Action of Ibrutinib
 
01:17
Jennifer Woyach, MD, Assistant Professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses BTK inhibition and the mechanism of action of ibrutinib. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Просмотров: 1306 Targeted Oncology
Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma
 
02:19
William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 619 Targeted Oncology
Dr. Tap on a Phase I Study of PLX3397 for PVNS
 
01:34
William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS). For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 1232 Targeted Oncology
The Deciding Factors for CML Treatment
 
04:44
Michael J. Mauro, MD, reviews the case of a 48-year-old female with relapsed chronic myeloid leukemia and discusses the deciding factors for choosing treatment. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 23177 Targeted Oncology
Dr. Bekaii-Saab on an Analysis of IPMN and Pancreatic Cancer Outcomes
 
01:30
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer outcomes. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 655 Targeted Oncology
Efficacy Results for LOXO-101 in TRK Fusion Cancers
 
00:54
David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Просмотров: 1044 Targeted Oncology
Dr. Oliver Sartor on Considerations, Controversy With PSA Testing in Prostate Cancer
 
02:35
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 286 Targeted Oncology
Dr. Fine on the Utility of CAPTEM in Chemo-Resistant Neuroendocrine Tumors
 
02:51
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 334 Targeted Oncology
Managing Side Effects With Sorafenib in HCC
 
03:19
Ghassan K. Abou-Alfa, MD, provides insight on the management of side effects from sorafenib in a patient with hepatocellular carcinoma, including when a dose reduction is needed. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 327 Targeted Oncology
Dr. Fanale Discusses Brentuximab Vedotin in CD30-Positive Lymphomas
 
02:27
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses brentuximab vedotin in CD30-positive lymphomas. Brentuximab vedotin is currently approved for Hodgkin lymphoma and anaplastic large cell lymphoma and is being looked at in other CD30-positive T-cell lymphomas. For more resources, visit: http://targetedhc.com/
Просмотров: 566 Targeted Oncology